These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
555 related articles for article (PubMed ID: 31856912)
1. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912 [TBL] [Abstract][Full Text] [Related]
2. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. Ma CJ; Huang CW; Yeh YS; Tsai HL; Hu HM; Wu IC; Cheng TL; Wang JY Oncol Res; 2017 May; 25(5):673-679. PubMed ID: 27938508 [TBL] [Abstract][Full Text] [Related]
3. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105 [TBL] [Abstract][Full Text] [Related]
4. FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer. Adenis A; Mazard T; Fraisse J; Chalbos P; Pastor B; Evesque L; Ghiringhelli F; Mollevi C; Delaine S; Ychou M BMC Cancer; 2021 May; 21(1):564. PubMed ID: 34001059 [TBL] [Abstract][Full Text] [Related]
5. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial. Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY Trials; 2016 Jan; 17():46. PubMed ID: 26811156 [TBL] [Abstract][Full Text] [Related]
6. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927 [TBL] [Abstract][Full Text] [Related]
7. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting. Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762 [TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257 [TBL] [Abstract][Full Text] [Related]
9. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258 [TBL] [Abstract][Full Text] [Related]
10. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Schultheis B; Folprecht G; Kuhlmann J; Ehrenberg R; Hacker UT; Köhne CH; Kornacker M; Boix O; Lettieri J; Krauss J; Fischer R; Hamann S; Strumberg D; Mross KB Ann Oncol; 2013 Jun; 24(6):1560-7. PubMed ID: 23493136 [TBL] [Abstract][Full Text] [Related]
11. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. Toffoli G; Cecchin E; Gasparini G; D'Andrea M; Azzarello G; Basso U; Mini E; Pessa S; De Mattia E; Lo Re G; Buonadonna A; Nobili S; De Paoli P; Innocenti F J Clin Oncol; 2010 Feb; 28(5):866-71. PubMed ID: 20038727 [TBL] [Abstract][Full Text] [Related]
12. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Marcuello E; Páez D; Paré L; Salazar J; Sebio A; del Rio E; Baiget M Br J Cancer; 2011 Jun; 105(1):53-7. PubMed ID: 21654688 [TBL] [Abstract][Full Text] [Related]
13. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966 [TBL] [Abstract][Full Text] [Related]
14. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462 [TBL] [Abstract][Full Text] [Related]
15. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692 [TBL] [Abstract][Full Text] [Related]
16. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Toffoli G; Sharma MR; Marangon E; Posocco B; Gray E; Mai Q; Buonadonna A; Polite BN; Miolo G; Tabaro G; Innocenti F Clin Cancer Res; 2017 Feb; 23(4):918-924. PubMed ID: 27507617 [No Abstract] [Full Text] [Related]
17. A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer. Sanoff HK; Deal AM; Patel J; Sorah JD; Gaddy J; O'Neil B; Turk A; Irvin W; Boles J; Lee MS; McRee A; Wardell AC; Weck KE; Basch E; Wood WA; Innocenti F Oncologist; 2024 Sep; 29(9):786-793. PubMed ID: 38837045 [TBL] [Abstract][Full Text] [Related]
18. Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study. Adenis A; Ghiringhelli F; Gauthier L; Mazard T; Evesque L; Evrard A; Chalbos P; Moussion A; Gourgou S; Ychou M Cancer Chemother Pharmacol; 2024 Sep; 94(3):443-452. PubMed ID: 38987363 [TBL] [Abstract][Full Text] [Related]
19. Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous Tsai HL; Chen PJ; Chen YC; Li CC; Chang TK; Su WC; Yin TC; Huang CW; Wang JY J Int Med Res; 2022 Jul; 50(7):3000605221110697. PubMed ID: 35822291 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]